Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Collaboration Announcement

11 Apr 2013 16:44

RNS Number : 1781C
Advanced Oncotherapy PLC
11 April 2013
 



ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or "the Company")

 

COLLABORATION ANNOUNCEMENT

 

Advanced Oncotherapy (AVO) is pleased to announce a newly established synergy collaboration between CERN and Application of Detectors and Accelerators to Medicine SA ("ADAM") .

 

A team of experts in accelerator and detector technology from CERN founded ADAM with Italian entrepreneur Dr Alberto Colussi in 2007. ADAM aims to capitalise on the know-how and infrastructure that CERN provides to build innovative accelerators for proton therapy and for conventional radiotherapy.

 

ADAM's research and development activities have focused on two main fields: the design and construction of compact linear accelerators for conventional radiotherapy, and of compact linear accelerators for proton therapy. The next phase of the collaboration, a newly established synergy between ADAM,CERN and AVO will complete the Proton Beam accelerator complex.

 

"For CERN the transfer of technology and know-how in the medical field is an important part of the impact of basic science on societal issues," says CERN Director of Accelerators and Technology Steve Myers. "This partnership is a pragmatic way to share our competences and know-how with industrial partners who are able to bring this innovative medical solution to the market."

 

 

For further information, please contact:

 

Michael Sinclair,

Chief Executive

Sandy Jamieson

Jon Levinson

Simon Hudson,

Advanced Oncotherapy Group Plc

Libertas Capital Corporate Finance Ltd

Peterhouse Corporate Finance

Tavistock Communications

0203 617 8739

(NOMAD & Joint Broker)

(Joint Broker)

(Financial PR & IR)

020 7569 9650

020 7469 0930

020 7920 3150

 

 

 

About Advanced Oncotherapy

 

Advanced Oncotherapy is a provider of new technology for innovative and patient-focused cancer treatments. These are technologies endorsed internationally by UK and global cancer clinicians, but not currently available in the NHS nor the private sector. Such initiatives build on the Group's 28.75% stake in Advanced Proton Solutions (Holdings) Ltd and its Oncotherapy Resources business focused on non-melanoma skin cancer and early stage breast cancer. Advanced Proton Solutions is pioneering the use of Proton Beam Therapy in the UK. They have secured planning approval for its first proton beam therapy center in the UK in the City of London. In 2011, over 70,000 patients were treated worldwide with proton beam therapy in 32 centres.

 

-ends-

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBUGDSXSBBGXB
Date   Source Headline
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility
1st Mar 20232:54 pmRNSSecured Convertible Note Facility & other matters
1st Mar 20232:05 pmRNSSecond Price Monitoring Extn
1st Mar 20232:00 pmRNSPrice Monitoring Extension
27th Jan 20234:53 pmEQSHardman & Co Research: Q&A on Advanced Oncotherapy (AVO): Current EV significantly below cumulative investment to date
18th Jan 20232:00 pmRNSOperational update
17th Jan 20233:10 pmEQSHardman & Co Research on Advanced Oncotherapy (AVO): Understanding the significance of 230MeV
30th Dec 20221:00 pmRNSTotal Voting Rights
30th Dec 20229:24 amRNSDirector/PDMR Shareholding
29th Dec 20223:12 pmRNSDirector/PDMR Shareholding
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 202212:40 pmRNSSecond Price Monitoring Extn
23rd Dec 202212:35 pmRNSPrice Monitoring Extension
12th Dec 20227:00 amRNSEquity Subscription and Issue of Warrants
1st Dec 20227:00 amRNSIssue of Equity
28th Nov 20227:00 amRNSStudy showcases the potential superiority of LIGHT
3rd Nov 20223:20 pmRNSInvestor / Analyst Event Update
31st Oct 20225:00 pmRNSTotal Voting Rights
27th Oct 20227:31 amRNSPresentation highlights superiority of LIGHT
21st Oct 20227:00 amRNSNotice of Investor / Analyst Event
18th Oct 20227:00 amRNSEquity Subscription and Issue of Warrants
30th Sep 20225:00 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSInterim Results
29th Sep 20227:15 amEQSHardman & Co Research on Advanced Oncotherapy: Major milestone achieved
27th Sep 202210:30 amRNSLIGHT accelerator fully operational
31st Aug 20225:00 pmRNSTotal Voting Rights
23rd Aug 20223:09 pmRNSUpdate re admission of Subscription Shares
19th Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
17th Aug 20225:30 pmRNSHolding(s) in Company
3rd Aug 20227:00 amRNSEquity Subscription and Issue of Warrants
29th Jul 20224:30 pmRNSResult of AGM
7th Jul 202212:30 pmRNSHolding(s) in Company
30th Jun 20225:00 pmRNSTotal Voting Rights
30th Jun 20229:00 amRNSFinal results for the year ended 31 December 2021
28th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
13th Jun 20227:00 amRNSEquity Subscription and Issue of Warrants
31st May 20225:00 pmRNSTotal Voting Rights
27th May 202212:17 pmRNSHolding(s) in Company
11th May 20227:00 amRNSLIGHT system potential in delivering FLASH
29th Apr 20225:00 pmRNSTotal Voting Rights
27th Apr 20227:00 amRNSVideo showcases progress on LIGHT system process
26th Apr 20227:00 amRNSOperational update
22nd Apr 20227:00 amRNSUpdate re admission of Subscription Shares
19th Apr 20224:05 pmRNSUpdate re admission of Subscription Shares
12th Apr 20227:13 amRNSEquity Subscription and Issue of Warrants
31st Mar 20225:00 pmRNSTotal Voting Rights
25th Mar 20229:30 amRNS£2m Subscription, Add'l Loan and Issue of Warrants
14th Mar 20227:15 amEQSHardman & Co Research: Advanced Oncotherapy (AVO) - LIGHT: regulatory update
4th Mar 20229:00 amRNSDirector/PDMR Notification
3rd Mar 20226:13 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.